Ironwood Pharmaceuticals Inc (IRWD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ironwood Pharmaceuticals Inc (IRWD) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.12 Million) by net assets ($-217.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IRWD net asset quality index to measure how much of total assets are equity-financed.
Ironwood Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Ironwood Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ironwood Pharmaceuticals Inc (IRWD) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Ironwood Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ironwood Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangxi GETO New Materials Corporation Limited
SHE:300986
|
0.017x |
|
GR Engineering Services Ltd
AU:GNG
|
0.558x |
|
Sweetgreen Inc
NYSE:SG
|
-0.004x |
|
Xiangpiaopiao Food Co Ltd
SHG:603711
|
0.071x |
|
Hubei Chaozhuo Aviation Technology Co. Ltd. A
SHG:688237
|
N/A |
|
SLR Investment Corp
NASDAQ:SLRC
|
0.049x |
|
Collins Foods Ltd
AU:CKF
|
0.166x |
|
Basilea Pharmaceutica AG
SW:BSLN
|
0.305x |
Annual Cash Flow Conversion Efficiency for Ironwood Pharmaceuticals Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Ironwood Pharmaceuticals Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Ironwood Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-261.83 Million | $127.04 Million | -0.485x | -41.20% |
| 2024-12-31 | $-301.33 Million | $103.55 Million | -0.344x | +35.12% |
| 2023-12-31 | $-346.30 Million | $183.43 Million | -0.530x | -226.22% |
| 2022-12-31 | $652.38 Million | $273.76 Million | 0.420x | -2.91% |
| 2021-12-31 | $605.91 Million | $261.89 Million | 0.432x | -83.96% |
| 2020-12-31 | $62.64 Million | $168.84 Million | 2.695x | +2443.52% |
| 2019-12-31 | $-93.25 Million | $10.72 Million | -0.115x | -131.86% |
| 2018-12-31 | $-196.37 Million | $-70.88 Million | 0.361x | +103.57% |
| 2017-12-31 | $9.85 Million | $-99.56 Million | -10.110x | -2552.05% |
| 2016-12-31 | $66.72 Million | $-25.43 Million | -0.381x | +66.09% |
| 2015-12-31 | $95.12 Million | $-106.93 Million | -1.124x | +36.02% |
| 2014-12-31 | $88.55 Million | $-155.57 Million | -1.757x | +75.43% |
| 2013-12-31 | $38.23 Million | $-273.36 Million | -7.151x | -1379.39% |
| 2012-12-31 | $144.05 Million | $-69.63 Million | -0.483x | +29.42% |
| 2011-12-31 | $109.86 Million | $-75.24 Million | -0.685x | -60.93% |
| 2010-12-31 | $159.55 Million | $-67.90 Million | -0.426x | -3275.65% |
| 2009-12-31 | $-298.34 Million | $-4.00 Million | 0.013x | -89.05% |
| 2008-12-31 | $-230.41 Million | $-28.20 Million | 0.122x | +222.94% |
| 2007-12-31 | $-178.37 Million | $-6.76 Million | 0.038x | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more